AndraValvulotome
AndraValvulotome
Do you have questions about this product? We are looking forward to your message.
David Feindel
About David Feindel
Posts by David Feindel:
Nit-Occlud® PFO
Nit-Occlud® PFO
Do you have questions about this product? We are looking forward to your message.
Transseptal needle and sheath
Do you have questions about this product? We are looking forward to your message.
AndraSnare
AndraSnare
Do you have questions about this product? We are looking forward to your message.
Flamingo inflation injection
Flamingo inflation injection
Do you have questions about this product? We are looking forward to your message.
Dolphin inflation injection
Dolphin inflation injection
Do you have questions about this product? We are looking forward to your message.
Direct-Stent® Stent Graft
Direct-Stent® Stent Graft
Do you have questions about this product? We are looking forward to your message.
AndraStent Aortic XL und XXL
AndraStent Aortic XL and XXL
Non-clinical testing has demonstrated the AndraStent Aortic and Covered AndraStent Aortic, represented by the Covered AndraStent ASC57XXL are MR Conditional. A patient with this device can be safely scanned in an MR system meeting the following conditions:
-
-
-
-
- Static magnetic field of 3 Tesla, with
- Maximum spatial field gradient of 7,200 G/cm (72 T/m)
- Maximum force product of 132,000,000 G2/cm (132 T2/m)
- Theoretically estimated maximum whole body averaged (WBA) specific absorption rate (SAR) of 2 W/kg (Normal Operating Mode)
-
-
-
Under the scan conditions defined above, the stent is expected to produce a maximum temperature rise of less than 3.2 °C (2 W/kg, 3 Tesla) RF-related temperature increase with a background temperature increase of around 1.0 °C (2 W/kg, 3 Tesla) after 15 minutes of continuous scanning.
In non-clinical testing, the image artefact caused by the device extends approximately 17.5 mm from the stent when imaged with a gradient echo pulse sequence and a 3 Tesla MR system
Do you have questions about this product? We are looking forward to your message.
CAAS 4D-Flow
4D-Flow: Complete assessment of your MR 4D Flow data
Caas MR 4D Flow is specifically designed to extract relevant information from 3D phase-contrast (PC) MR images, within a few clicks. Based on these phase-contrast images, two pioneering 4D Flow modules are offered to perform a complete flow analysis that can aid in reading and interpreting cardiovascular MR images and assist in planning the time and type of an intervention. These two modules include a module to analyze vessels, from the aorta up to smaller vessels in for example the kidneys (Caas MR 4D Artery), and a module to analyze the heart valves in terms of regurgitation fraction (Caas MR 4D Heart).
Key Results
- Visualization of aortic blood flow as streamlines, pathlines and color-coded vectors
- Distribution of wall shear stress and local values of wall shear stress
- Pressure difference over a segment
- Visualization and quantification of regurgitant fraction over all four valves
- 2D flow phase-contract analysis
The Wall Shear Stress Analysis and Pressure Difference Analysis are not CE marked and therefore not meant for clinical decision making.
CAAS A-Valve
CAAS A-Valve: assisting physicians during or in preparation of valve replacements as TAVR procedures.
CAAS A-Valve assists the physician in evaluating aortic regurgitation after transcatheter valve replacement. The qRA workflow (also called videodensitometry, VD-AR, LVOT-AR) enables the physician to quantify valvular and paravalvular regurgitation immediately in the hybrid OR directly after placing the valve.
Clinical confidence
qRA is extensively validated by the groups of Prof. Patrick Serruys and Prof. Carl Schulz. Validation studies have been performed in:
- Correlating with clinical endpoints to assess LVOT-AR cut-off value of 0.17
- Comparing with MR Flow measurements
- Comparing with echocardiography measurements
- Comparing with visual classification of aortic regurgitation
- Phantom setup
Use in practice
CAAS A-Valve qRA has been used to assess:
- Acute performance of a novel Xeltis valve in a pre-clinical setting
- Comparison of seven different TAVR valves
1 2